
<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">

    <title>Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. | Aparicio Lab</title>
    
    <meta name="author" content="Dr. Samuel Aparicio">

    <!-- Enable responsive viewport -->
    <meta name="viewport" content="width=device-width, initial-scale=1.0"/>

    <!-- Bootstrap styles -->
    <link href="/assets/themes/lab/bootstrap/css/bootstrap.min.css" rel="stylesheet"/>
    <!-- Optional theme -->
    <link href="/assets/themes/lab/bootstrap/css/bootstrap-theme.min.css" rel="stylesheet"/>
    <!-- Sticky Footer -->
    <link href="/assets/themes/lab/bootstrap/css/bs-sticky-footer.css" rel="stylesheet"/>

    <!-- Custom styles -->
    <link href="/assets/themes/lab/css/style.css?body=1" rel="stylesheet" type="text/css" media="all"/>

    <!-- icon -->
    <link rel="icon" type="image/png" href="/assets/themes/lab/images/logo/favicon.png"/>

    <!-- Custom fonts and icons via Font Awesome, http://fortawesome.github.io/Font-Awesome/ -->
    <link rel="stylesheet" href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css"/>

    <!-- Fonts via Google -->
    <link href='https://fonts.googleapis.com/css?family=Lato:300italic,700italic,300,700' rel='stylesheet' type='text/css'/>

    <!-- Math via MathJax -->
    <script type="text/javascript" src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>


    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->

    <!-- Fav and touch icons -->
    <!-- Update these with your own images
      <link rel="shortcut icon" href="images/favicon.ico">
      <link rel="apple-touch-icon" href="images/apple-touch-icon.png">
      <link rel="apple-touch-icon" sizes="72x72" href="images/apple-touch-icon-72x72.png">
      <link rel="apple-touch-icon" sizes="114x114" href="images/apple-touch-icon-114x114.png">
    -->

    <!-- atom & rss feed
    <link href="/atom.xml" type="application/atom+xml" rel="alternate" title="Sitewide ATOM Feed">
    <link href="/rss.xml" type="application/rss+xml" rel="alternate" title="Sitewide RSS Feed">
    -->

  </head>

  <body>

  <!-- Static top navbar -->
  
  <nav class="navbar navbar-expand-lg navbar-light bg-light">

    <div class="container-fluid" style="margin: 0px 80px 0px 80px;">
      <a href="/">
        <img class="pull-left logo" src="/assets/themes/lab/images/logo/lab-logo.svg" type="image/svg+xml">
      </a>
      
      
      
        <a class="navbar-brand" href="/">Aparicio Lab</a>
      
  
      <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
        <span class="navbar-toggler-icon"></span>
      </button>
      <div class="collapse navbar-collapse" id="navbarSupportedContent">
        <ul class="navbar-nav me-auto mb-2 mb-lg-0">
          
          <li class="nav-item">
            <a class="nav-link" href="/careers">Careers</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="/research">Research</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="/team">Team</a>
          </li>
          <li class="nav-item">
            <a class="nav-link" href="/papers">Papers</a>
          </li>
          
        </ul>
      </div>

    </div>

  </nav>


  <div class='container'>
      <!-- Brand and toggle get grouped for better mobile display-->

      <!-- Collect the nav links, forms, and other content for toggling 
      

        <ul class="nav navbar-nav navbar-right pull-right">
          
          
          


  
    
  
    
      
    
  
    
      
    
  
    
  
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
      
    
  
    
  
    
  
    
      
      	
      	<li><a href="/careers">Careers</a></li>
      	
      
    
  
    
      
      	
      	<li><a href="/research">Research</a></li>
      	
      
    
  
    
      
      	
      	<li><a href="/papers/">Papers</a></li>
      	
      
    
  
    
      
      	
      	<li><a href="/team/">Team</a></li>
      	
      
    
  



-->

   <!-- Content -->
   <div class="container">
      
<!-- 
Branched from Trevor Bedford's source, https://github.com/blab/blotter/blob/master/_layouts/paper.html
with gratitude.
-->

<div class="bigspacer"></div>

<div class="row">
	<div class="col-md-3">
		<div class="media">
			
			<img class="pull-left pad-right media-object paper-image" src="/assets/images/papers/25779558.jpg">
			
		</div>
	</div>

	<div class="col-md-9">
		<div class="media-body titlebox">
			<div class="title media-heading">
				Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
			</div>
			<p>
			<div class="smallhead">
				Karen A Gelmon, Frances M Boyle, Bella Kaufman, David G Huntsman, Alexey Manikhas, Angelo Di Leo, Miguel Martin, Lee S Schwartzberg, Julie Lemieux, Samuel Aparicio, Lois E Shepherd, Susan Dent, Susan L Ellard, Katia Tonkin, Kathleen I Pritchard, Timothy J Whelan, Dora Nomikos, Arnd Nusch, Robert E Coleman, Hirofumi Mukai, Sergei Tjulandin, Rustem Khasanov, Shulamith Rizel, Anne P Connor, Sergio L Santillana, Judith-Anne W Chapman, Wendy R Parulekar, 
				<span class="journal">
				Journal of clinical oncology : official journal of the American Society of Clinical Oncology <b>33</b>, 1574-83 (2015)
				</span>
				
				
				
				
			</div>
		</div>
	</div>
</div>

<div class="bigspacer"></div>

<div class="row">
	<div class="col-md-3">
		<div class="bigspacer"></div>
		<div class="glyphbox note"> <!-- DAD: what is this class? -->
			

			

			
						
			
			<div class="smallhead subtle">
				DOI
			</div>
			<div class="pad-left note">
				<div class="smallspacer"></div>
				<i class="fa fa-external-link fa-fw"></i>
				<a class="off" href="http://dx.doi.org/10.1200/JCO.2014.56.9590">10.1200/JCO.2014.56.9590</a>
			</div>
			<div class="bigspacer"></div>			
			
			
			
			
			
			
			<div class="smallhead subtle">
				Share
			</div>
		    <!-- Paste the 3 next lines where you want the sharing button(s) to appear -->
		    <div class="post-sharing">
		     

  
  		<!-- Twitter -->
<i class="fa fa-twitter fa-fw"></i>
<a class="off" href="https://twitter.com/share?url=&text=" data-text="Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31." data-via="" data-related="sajraparicio" target="_blank">tweet</a>

	


		    </div>

		</div>
	</div>
	
	<div class="col-md-8">	
		<div class="post">
			<p><br /></p>
<div data-badge-popover="right" data-badge-type="donut" data-pmid="25779558" data-hide-no-mentions="true" class="altmetric-embed"></div>

<h1 id="abstract">Abstract</h1>

<p>The efficacy of lapatinib versus trastuzumab combined with taxanes in the first-line setting of human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (BC) is unknown.</p>

<p>The MA.31 trial compared a combination of first-line anti-HER2 therapy (lapatinib or trastuzumab) and taxane therapy for 24 weeks, followed by the same anti-HER2 monotherapy until progression. Stratification was by prior (neo)adjuvant anti-HER2 therapy, prior (neo)adjuvant taxane, planned taxane, and liver metastases. The primary end point was intention-to-treat (ITT) progression-free survival (PFS), defined as time from random assignment to progression by RECIST (version 1.0) criteria, or death for patients with locally assessed HER2-positive tumors. The primary test statistic was a stratified log-rank test for noninferiority. PFS was also assessed for patients with centrally confirmed HER2-positive tumors.</p>

<p>From July 17, 2008, to December 1, 2011, 652 patients were accrued from 21 countries, resulting in 537 patients with centrally confirmed HER2-positive tumors. Median follow-up was 21.5 months. Median ITT PFS was 9.0 months with lapatinib and 11.3 months with trastuzumab. By ITT analysis, PFS was inferior for lapatinib compared with trastuzumab, with a stratified hazard ratio (HR) of 1.37 (95% CI, 1.13 to 1.65; P = .001). In patients with centrally confirmed HER2-positive tumors, median PFS was 9.1 months with lapatinib and 13.6 months with trastuzumab (HR, 1.48; 95% CI, 1.20 to 1.83; P &lt; .001). More grade 3 or 4 diarrhea and rash were observed with lapatinib (P &lt; .001). PFS results were supported by the secondary end point of overall survival, with an ITT HR of 1.28 (95% CI, 0.95 to 1.72; P = .11); in patients with centrally confirmed HER2-positive tumors, the HR was 1.47 (95% CI, 1.03 to 2.09; P = .03).</p>

<p>As first-line therapy for HER2-positive metastatic BC, lapatinib combined with taxane was associated with shorter PFS and more toxicity compared with trastuzumab combined with taxane.</p>


		</div>	
	</div>
	

	<div class="col-md-1"></div>
</div>

<div class="bigspacer"></div>



   </div>


  <!-- Static bottom navbar -->
  <nav class="navbar navbar-expand-lg navbar-light bg-light navbar-fixed-bottom">
    <div class="container-fluid">
      <!-- Collect the nav links, forms, and other content for toggling -->
      <div class="collapse navbar-collapse" id="jb-bottom-collapse">
        
        <div class = "col-md-2">
        <a class="logo-anchor" href="">
          <img class="logo" alt="" src="">
        </a>
        <a class="logo-anchor" href="http://www.bccancer.bc.ca/">
          <img class="logo" alt="BC Cancer" src="/assets/images/logos/bc_cancer.png">
        </a>
        <a class="logo-anchor" href="http://www.ubc.ca/">
          <img class="logo" alt="UBC" src="/assets/images/logos/ubc.png">
        </a>
        </div>
        <div class = "col-md-8"></div>
        <div class = 'float-right col-md-2'>
          <ul class="nav navbar-nav navbar-right navbar-small">
            <li><a href='/contact'><button type="button" class="btn btn-light"><h2>Contact</h2></button></a></li>
          </ul>
      </div>
      </div><!-- /.navbar-collapse -->
    </div>
  </nav>

    




  <script type="text/javascript">
  var _gaq = _gaq || [];
  _gaq.push(['_setAccount', 'UA-103919622-1']);
  _gaq.push(['_trackPageview']);

  (function() {
    var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
    ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
  })();
</script>




    <!-- Latest compiled and minified JavaScript, requires jQuery 1.x (2.x not supported in IE8) -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
    <script src="/assets/themes/lab/bootstrap/js/bootstrap.min.js"></script>
    <script type='text/javascript' src='https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js'></script>
  </body>
</html>

